Anastrozole vs Kisspeptin-10 (HPG Axis)
A side-by-side research comparison of Anastrozole and Kisspeptin-10 (HPG Axis) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Anastrozole | Kisspeptin-10 (HPG Axis) |
|---|---|---|
| Full name | Anastrozole (Arimidex) | Kisspeptin-10 (Metastin 45-54) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA-approved prescription | Research compound |
| Mechanism | Selectively and reversibly inhibits aromatase (CYP19A1), the enzyme that converts androgens to estrogens. Reduces circulating estradiol levels without affecting other steroid pathways. | Binds KISS1R (GPR54) receptors on GnRH neurons in the hypothalamus, triggering pulsatile GnRH release. This cascades to LH/FSH secretion from the pituitary, maintaining the natural feedback loop. |
| Molecular weight | 293.37 Da | 1302.5 Da |
| Half-life | ~46.8 hours | ~28 minutes (IV); ~4 hours (SubQ) |
| Bioavailability | ~80-85% oral | ~90% (subcutaneous) |
| Typical dose | 0.25-0.5 mg | 100-400 mcg |
| Frequency | 2-3x per week | 1-2x daily |
| Route | Oral tablet | Subcutaneous injection |
Anastrozole reported benefits
- Estrogen control
- Reduced water retention
- Prevention of gynecomastia
- Maintained testosterone ratio
- Improved body composition
Kisspeptin-10 (HPG Axis) reported benefits
- Natural testosterone restoration
- Preserved HPG axis function
- Enhanced libido
- LH/FSH stimulation
- Potential fertility support
- No testicular suppression
Related comparisons
Research and educational reference only. Not medical advice.